A randomized, controlled, phase 1/2 trial of a neisseria meningitidis serogroup B bivalent rLP2086 vaccine in healthy children and adolescents

Pediatric Infectious Disease Journal

Volumn 32, Issue 4, 2013, Pages 364-371

  Nissen, Michael D ^a   Marshall, Helen S ^b   Richmond, Peter C ^c,d   Jiang, Qin ^e   Harris, Shannon L ^e   Jones, Thomas R ^e   Jansen, Kathrin U ^e   Perez, John L ^e  

^a ROYAL CHILDREN'S HOSPITAL   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^e Pfizervaccine Research   (United States)

Author keywords

Adolescents; Children; Factor H binding protein; Meningococcal vaccines; Neisseria meningitidis serogroup B

Indexed keywords

BACTERIAL VACCINE; RLP2086 VACCINE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADOLESCENT; ANOREXIA; APPENDICITIS; ARTHRALGIA; ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; CHILD; CHILL; COMPLEMENT BLOOD LEVEL; CONTROLLED STUDY; COUGHING; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; FATIGUE; FEMALE; GASTROENTERITIS; HUMAN; IMMUNOGENICITY; INFLUENZA; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE SWELLING; MALE; MYALGIA; NAUSEA; NEISSERIA MENINGITIDIS; OTALGIA; OTITIS MEDIA; PRIORITY JOURNAL; SEROCONVERSION; TONSILLITIS; TOOTH PAIN; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

ADOLESCENT; ANTIGENS, BACTERIAL; AUSTRALIA; BACTERIAL PROTEINS; BLOOD BACTERICIDAL ACTIVITY; CHILD; DRUG TOXICITY; FEMALE; HUMANS; MALE; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS, SEROGROUP B; RECOMBINANT PROTEINS; SINGLE-BLIND METHOD; VACCINES, SYNTHETIC;

EID: 84876288781     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e31827b0d24     Document Type: Article

References (38)

1. Granoff DM, Harrison LH, Borrow R. Meningococcal vaccines. In: Plotkin SA, Orenstein WA, Offit P, eds. Vaccines. 5 ed. Philadelphia, PA: Saunders Elsevier; 2008:399-434.
2. van Deuren M, Brandtzaeg P, van der Meer JW. Update on meningococcal disease with emphasis on pathogenesis and clinical management. Clin Microbiol Rev. 2000;13:144-166, table of contents.
3. Thompson MJ, Ninis N, Perera R, et al. Clinical recognition of meningococcal disease in children and adolescents. Lancet. 2006;367:397-403.
4. Bilukha OO, Rosenstein N; National Center for Infectious Diseases, Centers for Disease Control and Prevention (CDC). Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2005;54(RR-7): 1-21.
5. Borg J, Christie D, Coen PG, et al. Outcomes of meningococcal disease in adolescence: prospective, matched-cohort study. Pediatrics. 2009;123:e502-e509.
6. Edmond K, Clark A, Korczak VS, et al. Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. Lancet Infect Dis. 2010;10:317-328.
7. Christensen H, May M, Bowen L, et al. Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect Dis. 2010;10:853-861.
8. Trotter CL, Gay NJ, Edmunds WJ. The natural history of meningococcal carriage and disease. Epidemiol Infect. 2006;134:556-566.
9. Ortega-Sanchez IR, Meltzer MI, Shepard C, et al.; Active Bacterial Core Surveillance Team. Economics of an adolescent meningococcal conjugate vaccination catch-up campaign in the United States. Clin Infect Dis. 2008;46:1-13.
10. Rosenstein NE, Perkins BA, Stephens DS, et al. Meningococcal disease. N Engl J Med. 2001;344:1378-1388.
11. Pace D, Pollard AJ. Meningococcal A, C, V, and W-135 polysaccharide- protein conjugate vaccines. Arch Dis Child. 2007;92:909-915.
12. Finne J, Leinonen M, Mäkelä PH. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet. 1983;2:355-357.
13. Rougon G, Dubois C, Buckley N, et al. A monoclonal antibody against meningococcus group B polysaccharides distinguishes embryonic from adult N-CAM. J Cell Biol. 1986;103(6, pt 1):2429-2437.
14. Bruge J, Bouveret-Le Cam N, Danve B, et al. Clinical evaluation of a group B meningococcal N-propionylated polysaccharide conjugate vaccine in adult, male volunteers. Vaccine. 2004;22:1087-1096.
15. Girard MP, Preziosi MP, Aguado MT, et al. A review of vaccine research and development: meningococcal disease. Vaccine. 2006;24:4692-4700.
16. Tappero JW, Lagos R, Ballesteros AM, et al. Immunogenicity of 2 sero-group B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile. JAMA. 1999;281:1520-1527.
17. Tondella ML, Popovic T, Rosenstein NE, et al. Distribution of Neisseria meningitidis serogroup B serosubtypes and serotypes circulating in the United States. The Active Bacterial Core Surveillance Team. J Clin Microbiol. 2000;38:3323-3328.
18. Chiu C, Dey A, Wang H, et al. Vaccine preventable diseases in Australia, 2005 to 2007. Commun Dis Intell. 2010;34 Supp:S1-167.
19. Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine. 2009;27 Suppl 2:B51-B63.
20. Racloz VN, Luiz SJ. The elusive meningococcal meningitis serogroup: a systematic review of serogroup B epidemiology. BMC Infect Dis. 2010;10:175.
21. Fletcher LD, Bernfield L, Barniaky et al. Vaccine potential of the Neisseria meningitidis 2086 lipoprotein. Infect Immun. 2004;72:2088-2100.
22. Masignani V, Comanducci M, Giuliani MM, et al. Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J Exp Med. 2003;197:789-799.
23. Murphy E, Andrew L, Lee KL, et al. Sequence diversity of the factor H binding protein vaccine candidate in epidemiologic ally relevant strains of serogroup B Neisseria meningitidis. J Infect Dis. 2009;200:379-389.
24. McNeil LK, Murphy E, Zhao XJ, et al. Detection of LP2086 on the cell surface of Neisseria meningitidis and its accessibility in the presence of serogroup B capsular polysaccharide. Vaccine. 2009;27:3417-3421.
25. Madico G, Welsch JA, Lewis LA, et al. The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance. J Immunol. 2006;177:501-510.
26. Pajon R, Beernink PT, Harrison LH, et al. Frequency of factor H-binding protein modular groups and susceptibility to cross-reactive bactericidal activity in invasive meningococcal isolates. Vaccine. 2010;28:2122-2129.
27. Jiang HQ, Hoiseth SK, Harris SL, et al. Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease. Vaccine. 2010;28:6086-6093.
28. Ala'aldeen DA, Flint M, Oldfield NJ, et al. Human antibody responses to the meningococcal factor H binding protein (LP2086) during invasive disease, colonization and carriage. Vaccine. 2010;28:7667-7675.
29. Richmond PC, Nissen MD, Marshall HS, et al. A bivalent Neisseria meningitidis recombinant lipidated factor H binding protein vaccine in young adults: results of a randomised, controlled, dose-escalation phase 1 trial. Vaccine. 2012;30:6163-6174.
30. Marshall HS, Richmond PC, Nissen MD, et al. Safety and immunogenic ity of a meningococcal B bivalent rLP2086 vaccine in healthy toddlers aged 18-36 months: a phase 1 randomized-controlled clinical trial. Pediatr Infect Dis J. 2012;31:1061-1068.
31. Tan LK, Carlone GM, Borrow R Advances in the development of vaccines against Neisseria meningitidis. N EnglJ Med. 2010;362:1511-1520.
32. Anderson AS, Jansen KU, Eiden J. New frontiers in meningococcal vaccines. Expert Rev Vaccines. 2011;10:617-634.
33. Panatto D, Amicizia D, Lai PL, et al. Neisseria meningitidis B vaccines. Expert Rev Vaccines. 2011;10:1337-1351.
34. Bai X, Findlow J, Borrow R Recombinant protein meningococcal serogroup B vaccine combined with outer membrane vesicles. Expert Opin Biol Ther. 2011;11:969-985.
35. Giuliani MM, Adu-Bobie J, Comanducci M, et al. A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci USA. 2006; 103:10834-10839.
36. Keiser PB, Biggs-Cicatelli S, Moran EE, et al. A phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxLl and synX, over-expressed factor H binding protein, two PorAs and stabilized OpcA expression. Vaccine. 2011;29:1413-1420.
37. Richmond PC, Marshall HS, Nissen MD, et al.; 2001 Study Investigators. Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis. 2012;12:597-607.
38. Sheldon E, Schwartz H, Jiang Q, et al. A phase 1, randomized, open-label, active-controlled trial to assess the safety of a meningococcal serogroup B bivalent rLP2086 vaccine in healthy adults. Hum Vaccin Immunother. 2012;8:888-895.